Total DNA methylation as a biomarker of DNA damage and tumor malignancy in intracranial meningiomas

BMC Cancer. 2020 Jun 3;20(1):509. doi: 10.1186/s12885-020-06982-3.

Abstract

Background: Meningiomas are the most common primary intracranial tumors in adults. They are initially detected with neuroimaging techniques, but definite histological diagnosis requires tumor surgery to collect tumor tissue. Gross total resection is an optimal and final treatment for the majority of patients, followed by radiotherapy in malignant or refractory cases. However, there are a lot of uncertainties about i.a. the need for intervention in incidental cases, estimation of growth kinetics, risk of malignant transformation, or response to radiotherapy. Therefore a new diagnostic approach is needed. It has already been shown that epigenetics plays a crucial role in cancer biology, development, and progression. DNA methylation, the presence of 5-methylcytosine in DNA, is one of the main elements of a broad epigenetic program in a eukaryotic cell, with superior regulatory significance. Therefore, we decided to look at meningioma through changes of 5-methylcytosine.

Methods: We performed an analysis of the total amount of 5-methylcytosine in DNA isolated from intracranial meningioma tissues and peripheral blood samples of the same patients. The separation and identification of radioactively labeled nucleotides were performed using thin-layer chromatography.

Results: We found that the 5-methylcytosine level in DNA from intracranial meningiomas is inversely proportional to the malignancy grade. The higher the tumor WHO grade is, the lower the total DNA methylation. The amount of 5-methylcytosine in tumor tissue and peripheral blood is almost identical.

Conclusions: We conclude that the total DNA methylation can be a useful marker for brain meningioma detection, differentiation, and monitoring. It correlates with tumor WHO grade, and the 5-methylcytosine level in peripheral blood reflects that in tumor tissue. Therefore it's applicable for liquid biopsy. Our study creates a scope for further research on epigenetic mechanisms in neurooncology and can lead to the development of new diagnostic methods in clinical practice.

Keywords: 5-methylcytosine; Biomarker; DNA damage; DNA methylation; Meningioma.

MeSH terms

  • 5-Methylcytosine / blood
  • 5-Methylcytosine / metabolism*
  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor / blood
  • Biomarkers, Tumor / metabolism*
  • DNA / blood
  • DNA / metabolism
  • DNA Damage
  • DNA Methylation*
  • Diagnosis, Differential
  • Epigenesis, Genetic
  • Female
  • Humans
  • Liquid Biopsy / methods
  • Male
  • Meningeal Neoplasms / blood
  • Meningeal Neoplasms / diagnosis*
  • Meningeal Neoplasms / genetics
  • Meningeal Neoplasms / surgery
  • Meninges / pathology
  • Meninges / surgery
  • Meningioma / blood
  • Meningioma / diagnosis*
  • Meningioma / genetics
  • Meningioma / surgery
  • Middle Aged
  • Young Adult

Substances

  • Biomarkers, Tumor
  • 5-Methylcytosine
  • DNA